|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has become the most common liver disorder in Western countries and is increasingly being recognized in developing nations.Fatty liver disease encompasses a spectrum of hepatic pathology,ranging from simple steatosis to non-alcoholic steatohepatitis,cirrhosis,hepatocellular carcinoma and end-stage liver disease.Moreover,NAFLD is often associated with other metabolic conditions,such as diabetes mellitus type 2,dyslipidemia and visceral obesity.The most recent guidelines suggest the management and treatment of patients with NAFLD considering both the liver disease and the associated metabolic co-morbidities.Diet and physical exercise are considered the first line of treatment for patients with NAFLD,but their results on therapeutic efficacy are often contrasting.Behavior therapy is necessary most of the time to achieve a sufficient result.Pharmacological therapy includes a wide variety of classes of molecules with different therapeutic targets and,often,little evidence supporting the real efficacy.Despite the abundance of clinical trials,NAFLD therapy remains a challenge for the scientific community,and there are no licensed therapies for NAFLD.Urgently,new pharmacological approaches are needed.Here,we will focus on the challenges facing actual therapeutic strategies and the most recent investigated molecules. | Alessandro Federico Claudio Zulli Ilario de Sio Anna Del Prete Marcello Dallio Mario Masarone Carmela Loguercio | 2014 | World Journal of Gastroenterology2014，20，45： | 10 |
| 2 | Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis:Differences and similarities显示文摘AIM:To investigate the prevalence of the clinical parameters of insulin resistance and diabetes in patients affected by chronic hepatitis C(CHC) or chronic hepatitis B(CHB) . METHODS:We retrospectively evaluated 852 consecutive patients(726 CHC and 126 CHB) who had undergone liver biopsy.We recorded age,sex,ALT,type 2 diabetes and/or metabolic syndrome(MS) ,body mass index(BMI) ,and apparent disease duration(ADD) . RESULTS:Age,ADD,BMI,prevalence of MS and diabetes in patients with mild/moderate liver fibrosis were significantly higher in CHC.However,the degree of steatosis and liver fibrosis evaluated in liver biopsies did not differ between CHC and CHB patients.At multivariate analysis,age,sex,BMI,ALT and diabetes were independent risk factors for liver fibrosis in CHC,whereas only age was related to liver fibrosis in CHB. We also evaluated the association between significant steatosis(>30%) and age,sex,BMI,diabetes,MS and liver fibrosis.Diabetes,BMI and liver fibrosis were associated with steatosis>30%in CHC,whereas only age and BMI were related to steatosis in CHB. CONCLUSION:These data may indicate that hepatitis C virus infection is a risk factor for insulin resistance. | Marcello Persico Mario Masarone Vincenzo La Mura Eliana Persico Francesco Moschella Monica Svelto Savino Bruno Roberto Torella | 2009 | World Journal of Gastroenterology2009，15，4： | 8 |
| 3 | Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3显示文摘Hepatitis C virus(HCV) infection is a common chronic liver disease worldwide.Non-alcoholic fatty liver disease and insulin resistance(IR) are the major determinants of fibrosis progression and response to antiviral therapy.The pathogenetic link between IR and chronic HCV infection is complex,and is associated with HCV genotype.Liver steatosis is the most common in the patients infected with genotype 3 virus,possibly due to direct effects of genotype 3 viral proteins.To the contrary,hepatic steatosis in the patients infected with other genotypes is thought to be mostly due to the changes in host metabolism,involving IR.In HCV genotype 3,liver steatosis correlates with viral load,reverts after reaching the sustained virologic response and reoccurs in the relapsers.A therapeutic strategy to improve IR and liver steatosis and subsequently the response to antiviral treatment in these patients is warranted. | Ludovico Abenavoli Mario Masarone Valentina Peta Natasa Milic Nazarii Kobyliak Samir Rouabhia Marcello Persico | 2014 | World Journal of Gastroenterology2014，20，41： | 7 |
| 4 | Viral hepatitis:Milestones,unresolved issues,and future goals显示文摘In this review the current overall knowledge on hepatitis A,B,C,D,and E will be discussed.These diseases are all characterized by liver inflammation but have significant differences in distribution,transmission routes,and outcomes.Hepatitis B virus and hepatitis C virus are transmitted by exposure to infected blood,and in addition to acute infection,they can cause chronic hepatitis,which in turn can evolve into cirrhosis.It is estimated that more than 300 million people suffer from chronic hepatitis B or C worldwide.Hepatitis D virus,which is also transmitted by blood,only affects hepatitis B virus infected people,and this dual infection results in worse liver-related outcomes.Hepatitis A and E spread via the fecal-oral route,which corresponds mainly to the ingestion of food or water contaminated with infected stools.However,in developed countries hepatitis E is predominantly a zoonosis.Although hepatitis A virus and hepatitis E virus are usually responsible for a self-limiting hepatitis,a serious,rarely fatal illness is also possible,and in immunosuppressed patients,such as organ transplant recipients,hepatitis E virus infection can become chronic.The description of goals achieved,unresolved issues,and the latest research on this topic may make it possible to speculate on future scenarios in the world of viral hepatitis. | Pietro Torre Andrea Aglitti Mario Masarone Marcello Persico | 2021 | World Journal of Gastroenterology2021，27，28： | 5 |
| 5 | Non Alcoholic Fatty Liver: Epidemiology and Natural History显示文摘 | Mario Masarone Alessandro Federico Ludovico Abenavoli Carmela Loguercio Marcello Persico | 2014 | Reviews on Recent Clinical Trials2014，，3： | 4 |
| 6 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course 显示文摘 | Limongelli G Masarone D D' Alessandro R | 2012 | Future Cardiol2012，8，1： | 1 |
| 7 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course 显示文摘 | Limongelli G Masarone D D'Alessandro R | 2012 | Future Cardiol2012，8，1： | 1 |
| 8 | Rapid virological response represents the highest prediction factor of response to antiviral treatment in HCV- related chronic hepatitis = a multicenter retrospective study显示文摘 | FEDERICO A MASARONE M ROMANO M | 2015 | Hepat Mon2015，15，6： | 1 |
| 9 | Antiviral therapy: why does it fail in HCV-related chronic hepatitis? 显示文摘 | Masarone M Persico M | 2011 | Expert Rev Anti Infect Ther2011，9，5： | 1 |
| 10 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course显示文摘 | Limongelli G Masarone D DAlessandro R | 2012 | Future Cardiol2012，8，1： | 1 |
| 11 | Interleukin-10?1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection显示文摘 | Marcello Persico Mario Capasso Eliana Persico Mario Masarone Amalia De Renzo Daniela Spano Savino Bruno Achille Iolascon | 2006 | Journal of Hepatology2006，，6： | 1 |
| 12 | Non alcoholic fatty liver: epidemiology and natural history 显示文摘 | Masarone M Federico A Abenavoli L | 2014 | Rev Recent Clin Trials2014，9，3： | 1 |
| 13 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course 显示文摘 | Limongelli G Masarone D D' Alessandro R | 2012 | Future Cardiol2012，8，1： | 1 |
| 14 | The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis显示文摘 | B. Palmentieri I. de Sio V. La Mura M. Masarone R. Vecchione S. Bruno R. Torella M. Persico | 2006 | Digestive and Liver Disease2006，，7： | 1 |
| 15 | Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori 显示文摘 | ABENAVOLI L MILIC N MASARONE M | 2013 | Med Hypotheses2013，81，5： | 1 |
| 16 | The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV- related chronic hepatitis显示文摘 | Loguercio C Federico A Masarone M | 2008 | J Biol Chem2008，103，12： | 1 |
| 17 | Interleukin-10?1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection显示文摘 | Marcello Persico Mario Capasso Eliana Persico Mario Masarone Amalia De Renzo Daniela Spano Savino Bruno Achille Iolascon | 2006 | Journal of Hepatology2006，，6： | 1 |
| 18 | Non alcoholic fatty liver: epidemiology and natural history 显示文摘 | MASARONE M FEDERICO A ABENAVOLI L | 2014 | Reviews on Recent Clinical Trials2014，9，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员